冷凍乾燥藥物、重組器材和注射市場:產品、市場、療法、策略和預測
市場調查報告書
商品編碼
1534275

冷凍乾燥藥物、重組器材和注射市場:產品、市場、療法、策略和預測

Lyophilized Drugs, Reconstitution Devices and Injection Markets: Products, Markets, Therapeutics, Strategies & Forecasts

出版日期: | 出版商: Greystone Research Associates | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

近年來,以冷凍乾燥製劑形式輸送的藥物數量持續增加,反映出生物製劑的不斷增加。需要冷藏直至配藥(稱為冷鏈)的液體藥物可以配製為粉末,以避免冷藏成本和物流。有許多因素將影響未來對冷凍乾燥藥物的需求。也許最重要的是製藥和生物技術市場的潛在動態,因為它們適用於藥物配方和最終用戶的要求。

本報告研究了冷凍乾燥藥物、重組器材和注射劑市場,並提供了市場概況、治療需求趨勢、到2026年的市場資料和預測以及市場參與者的概況。

目錄

執行摘要

  • 用於 POC 重新配置的整合設備
  • 雙室筒匣
  • 雙室注射器
  • 雙室注射器
  • 穿戴式裝置自動重新設定係統
  • 設備評估
  • 產品特定設備
  • MiniQuick(Vetter)
  • 特殊設備
  • Caverject Impulse(Hospira/Pfizer)
  • OEM 設備
  • Lyoject(Vetter)
  • DCP(SHL)
  • Dual Chamber Safety Syringe(Credence Medsystems)
  • Liquid Dry(Becton Dickinson)
  • LyoTwist Trio/Vario(Ypsomed)
  • LyoTwist Trio S/Vario S(Ypsomed)
  • V-LK(維特爾)
  • 市場機會
  • 冷凍乾燥藥品市場動態
  • 冷凍乾燥藥物的經濟學
  • 是什麼推動了凍乾藥品市場的發展?
  • 自我管理的趨勢
  • 人口統計變化
  • 一次性設備設計的創新
  • 競爭狀況
  • 推動治療需求的因素
  • 風險因素
  • 冷凍-冷凍乾燥藥物 - 初級包裝
  • 藥物重構
  • 雙室筒匣
  • 雙室注射器
  • 預充填稀釋劑注射器
  • 多步驟裝置
  • 人體工學
  • 重點治療領域分析及市場資料
  • 抗生素和感染
  • 免疫
  • 心臟病學和血液因素
  • 代謝狀態
  • 血糖控制
  • 開發階段雙室注射
  • 骨質疏鬆症
  • 荷爾蒙
  • 神經病學
  • 腫瘤學
  • 生殖健康
  • 勃起功能障礙
  • 市場因素
  • 監理問題
  • 醫療保健經濟
  • 治療領域 - 資料和預測
  • 荷爾蒙替代療法
  • Genotropin(Pfizer)
  • 代謝狀態
  • 骨質疏鬆症
  • 神經病學
  • Abilify Maintena(Otsuka America Pharmaceutical)
  • 腫瘤學
  • Luclin(Abbott Australasia Pty)
  • 生殖健康
  • Caverject Impulse(Hospira/Pfizer)
  • Edex/alprostadil(Actient)
  • Lupron Depot(AbbVie)
  • 其他治療領域
  • Prostap(Takeda)

公司簡介

簡介目錄

"Lyophilized Drugs, Reconstitution Devices, and Injection Markets: Therapeutics, Strategies and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for lyophilized injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

The number of drugs supplied in lyophilized form has been growing at an increased rate over the past several years, mirroring the increase in the introduction of biological drugs. Liquid drugs that require refrigeration until dispensed - a requirement referred to as the 'Cold Chain' - can be formulated as powders to avoid the cost and logistics of cold storage. A number of factors are at play that are likely to influence the future demand picture for lyophilized drugs. Perhaps the most important is the underlying dynamics of the pharmaceutical and biotechnology marketplace as they apply to drug formulation and end user requirements.

What You Will Learn:

  • Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
  • Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
  • Analyzes reconstitution technologies and market development issues
  • Provides market data and forecasts to 2026
  • Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of technology and regulatory factors on commercialization and market access

Table of Contents

Executive Summary

  • Integrated Devices for POC Reconstitution
  • Dual Chamber Cartridges
  • Dual Chamber Injectors
  • Dual Chamber Syringes
  • Wearable Device Automated Reconstitution Systems
  • Device Assessments
  • Product-Specific Devices
  • MiniQuick (Vetter)
  • Specialty Devices
  • Caverject Impulse (Hospira/Pfizer)
  • OEM Devices
  • Lyo-Ject (Vetter)
  • DCP (SHL)
  • Dual Chamber Safety Syringe (Credence Medsystems)
  • Liquid Dry (Becton Dickinson)
  • LyoTwist Trio/Vario (Ypsomed)
  • LyoTwist Trio S/Vario S (Ypsomed)
  • V-LK (Vetter)
  • The Market Opportunity
  • Lyophilized Drug Market Dynamics
  • The Economics of lyophilized Drugs
  • What's Driving the Market for Lyophilized Drugs?
  • The Trend toward Self-Administration
  • Shifting Demographics
  • Innovation in Disposable Device Designs
  • Competitive Landscape
  • Therapeutic Demand Drivers
  • Risk Factors
  • Lyophilized Drugs - Primary Packaging
  • Drug Reconstitution
  • Dual Chamber Cartridges
  • Dual Chamber Syringes
  • Prefilled Diluent Syringes
  • Multi-Step Devices
  • Human Engineering/Ergonomics
  • Key Therapeutic Sector Analysis & Market Data
  • Antibiotics & Infectious Diseases
  • Immune
  • Cardiology & Blood Factors
  • Metabolic Conditions
  • Glycemic Control
  • Development Stage Dual Chamber Injectable Drug Products
  • Osteoporosis
  • Hormones
  • Neurology
  • Oncology
  • Reproductive Health
  • Erectile Dysfunction
  • Market Factors
  • Regulatory Issues
  • Healthcare Economics
  • Therapeutic Segments - Data & Forecasts
  • Hormone Replacement
  • Genotropin (Pfizer)
  • Metabolic Conditions
  • Osteoporosis
  • Neurology
  • Abilify Maintena (Otsuka America Pharmaceutical)
  • Oncology
  • Lucrin (Abbott Australasia Pty)
  • Reproductive Health
  • Caverject Impulse (Hospira/Pfizer)
  • Edex/alprostadil (Actient)
  • Lupron Depot (AbbVie)
  • Other Therapeutic Segments
  • Prostap (Takeda)

Company Profiles